Trial Profile
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 26 Dec 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 26 Dec 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.